Kennedy has promised to "Make America Healthy Again" by tackling obesity with nutrition. Here's how he could rattle the ...

Levi & Korsinsky, LLP notifies investors in Metagenomi, Inc. ("Metagenomi" or the "Company") of a class action securities ...

Leerink Partners analyst Mani Foroohar has reiterated their bearish stance on MRNA stock, giving a Sell rating on November 14.Don't Miss our ...

Shares of vaccine makers such as Moderna (MRNA) and Pfizer (PFE) have plunged on news that president-elect Donald <a ...

The news sent Moderna (MRNA) down by 5.62% to close at $39.77 ... Pfizer (PFE), a partner in the COVID vaccine development ...

Experts warn of an expected winter COVID-19 surge, potentially impacting marginalized communities that have faced disproportionate effects since the pandemic began. Health advocates emphasize the need ...

President-elect Donald Trump's nomination of Robert F. Kennedy Jr. to lead the nation’s top health agency sent healthcare stocks sliding last week.  Vaccine makers like Moderna (MRNA) were down more ...

B.Riley Financial analyst Mayank Mamtani has maintained their bullish stance on NVAX stock, giving a Buy rating on November 13.Don't Miss our ...

Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.

The survey also found that small business owners saw many perceived benefits for AI, with 67% saying it can help save time, ...

Shares in biotech firm Moderna (NASDAQ:MRNA) rose more than 4% Monday after HSBC raised its rating on the stock from Hold to Buy while trimming the target price to $58 from $82.

Moderna’s (NASDAQ:MRNA) steep fall on Friday after President-elect Donald Trump selected vaccine critic Robert F. Kennedy Jr.